title: Rapid and quantitative detection of human septin family Bradeion as a practical diagnostic method of colorectal and urologic cancers.
abstract: BACKGROUND
  Malignant tumor progression is a complex and multi-gene event which can not be easily detected or predicted. The detection of malignant cells using marker genes is hampered by the fact that these markers are only expressed by certain malignancies or lack sensitivity and/or specificity. We have reported a human septin family gene Bradeion, which shows strong cancer-specific expression in colorectal and urologic cancers as a result of carcinogenesis.
  
  
  METHODS
  Diagnostic efficacy and validity of Bradeion gene expression were tested by two independent systems, one is a protein detection method using monoclonal antibody based immuno-chromatographic membrane strip tests (a nitrocellulose test strip assay), and another is a gene expression detection method, quantitative RT-PCR. The technology has been established using Bradeion fusion proteins, in vitro cultivated human cancer cell lines, and also patients' test samples with controls.
  
  
  RESULTS
  Bradeion test strip by combination with two monoclonal antibodies are valid for the detection of 1 ng/ml Bradeion, and successfully applied for patient urine samples with no false-positive results. Positive detection rates were over 70% of the patient urine samples so far tested (prostate cancer, renal cell carcinoma, and bladder cancer) in 15 to 30 minutes. Quantitative RT-PCR resulted in significantly high copy numbers of 0.4-3.0-3.0 x 10(5) per microg total RNA in patients' tissue samples, whereas those from normal tissue or other cancers found negative.
  
  
  CONCLUSIONS
  The present study introduces the practical diagnostic methods using a disease-specific molecular marker, which provides safe, economical, and rapid clinical screening of cancer.
authors.affiliation: National Institute of Advanced Industrial Science and Technology, Tsukuba Science City, Ibaraki, Japan. tanaka-manami@aist.go.jp
authors.forename: Manami
authors.initials: M
authors.lastname: Tanaka
authors.forename: Tomoo
authors.initials: T
authors.lastname: Tanaka
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Matsuzaki
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Seto
authors.forename: Taroh
authors.initials: T
authors.lastname: Matsuda
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Komori
authors.forename: Johbu
authors.initials: J
authors.lastname: Itoh
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kijima
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Tamai
authors.forename: Mayumi
authors.initials: M
authors.lastname: Shibayama
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Hideo
authors.initials: H
authors.lastname: Nakazawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Toma
mesh_terms: D000818:Animals; D001681:Biological Assay / Q000379:methods; D014408:Biomarkers, Tumor; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology; D003598:Cytoskeletal Proteins / Q000032:analysis* / Q000235:genetics; D018450:Disease Progression; D020558:GTP Phosphohydrolases / Q000032:analysis* / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D005810:Multigene Family; D011993:Recombinant Fusion Proteins / Q000032:analysis / Q000235:genetics; D015203:Reproducibility of Results; D014571:Urologic Neoplasms / Q000737:chemistry* / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D003598:Cytoskeletal Proteins; D011993:Recombinant Fusion Proteins; D020558:GTP Phosphohydrolases